EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Targeting cell membrane sphingolipids: a novel ceramide analog CeY-B1 inhibits migration and invasion in cervical cancer cells

Weiwei Tang, Hongliang Ma, Jingjing Li, Yunxia Kuang, Xiuqiong Meng, Ruyu Zeng, Tianli Yu, L M Yin, Yongmin Zhang, Yanli Cui, Jiangchao Li iD

Journal of Translational Medicine · 28.03.2026 · 24 (1)

DOI: 10.1186/s12967-026-08031-2 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Translational Medicine, online erschienen am 28.03.2026. Verfasst von Weiwei Tang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Oncology and Immunology, School of Basic Medical Sciences, Guangdong Pharmaceutical University, No. 280 Waihuan Rd. E, Higher Education…. Hauptthemen laut MEDLINE: Ceramides, Cell Movement, Uterine Cervical Neoplasms, Sphingolipids. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Key R&D Program of China, Cultural Relics Conservation Science and Technology Foundation of Zhejiang Province, Zhejiang Province"San Nong Jiu Fang"Science and Technology Cooperation Plan.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CeramidesCell MovementUterine Cervical NeoplasmsSphingolipidsCell MembraneFemaleHumansAnimalsCell Line, TumorNeoplasm InvasivenessXenograft Model Antitumor AssaysApoptosisSignal TransductionCell ProliferationMice, NudeMiceLipidomicsMice, Inbred BALB CCell Cycle Checkpoints

Stichwörter der Autor:innen

Cancer therapyCeramide derivativeCeramide metabolismCervical cancerLipidomics

Substanzen

CeramidesSphingolipids

Autor:innen und Institutionen

  • Laboratory of Oncology and Immunology, School of Basic Medical Sciences, Guangdong Pharmaceutical University, No. 280 Waihuan Rd. E, Higher Education Mega Center, Guangzhou, 510006, China.
  • Fuyang Institute & School of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou, 311422, China.
  • Sorbonne Université, CNRS, UMR 8232, 4 Place Jussieu, Paris, 75005, France.
  • Department of Chemistry, Zhejiang University, 886 Yuhangtang Road, Hangzhou, 310058, China. cuiyl@zju.edu.cn.
  • Laboratory of Oncology and Immunology, School of Basic Medical Sciences, Guangdong Pharmaceutical University, No. 280 Waihuan Rd. E, Higher Education Mega Center, Guangzhou, 510006, China. lijiangchao@gdpu.edu.cn.

ORCID-Profile: Jiangchao Li

Förderung

  • National Key R&D Program of China
  • Cultural Relics Conservation Science and Technology Foundation of Zhejiang Province
  • Zhejiang Province"San Nong Jiu Fang"Science and Technology Cooperation Plan
  • Science and Technology Planning Project of Guangdong Province
  • Key Engineering Team, Discipline Cultivation Projects, Guangdong Pharmaceutical University
  • Zhejiang Province“San Nong Jiu Fang”Science and Technology Cooperation Plan

Zitieren

APA

Tang, W., Ma, H., Li, J., Kuang, Y., Meng, X., Zeng, R., Yu, T., Yin, L. M., Zhang, Y., Cui, Y., & Li, J. (2026). Targeting cell membrane sphingolipids: a novel ceramide analog CeY-B1 inhibits migration and invasion in cervical cancer cells. Journal of Translational Medicine, 24(1). https://doi.org/10.1186/s12967-026-08031-2

Vancouver

Tang W, Ma H, Li J, Kuang Y, Meng X, Zeng R, et al. Targeting cell membrane sphingolipids: a novel ceramide analog CeY-B1 inhibits migration and invasion in cervical cancer cells. Journal of Translational Medicine. 2026;24(1). doi:10.1186/s12967-026-08031-2

BibTeX
@article{Tang2026,
  author = {Tang, Weiwei and Ma, Hongliang and Li, Jingjing and Kuang, Yunxia and Meng, Xiuqiong and Zeng, Ruyu and Yu, Tianli and Yin, L M and Zhang, Yongmin and Cui, Yanli and Li, Jiangchao},
  title = {Targeting cell membrane sphingolipids: a novel ceramide analog CeY-B1 inhibits migration and invasion in cervical cancer cells},
  journal = {Journal of Translational Medicine},
  year = {2026},
  volume = {24},
  number = {1},
  doi = {10.1186/s12967-026-08031-2}
}
Kostenlos starten →